898552-72-2

Upstream product

• 75-36-5 acetyl chloride 
• 195447-82-6 4-amino-3,3-dimethylbutanoic acid ethyl ester 
• 638-10-8 ethyl 3-methylbut-2-enoate 
• 130912-54-8 3,3-dimethyl-4-nitro-butyric acid ethyl ester 
• 66899-02-3 4,4-dimethylpyrrolidin-2-one 

Downstream Products

• 1310680-18-2 4-[((tert-butoxy)carbonyl)amino]-3,3-dimethylbutanoic acid 
• 898552-42-6 4-[2-(4-chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-3,3-dimethyl-butyric acid 
• 898552-41-5 4-[2-(4-Chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-3,3-dimethyl-butyric acid ethyl ester 
• 898552-39-1 3,3-Dimethyl-4-[2-(4-nitro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-butyric acid 
• 898552-44-8 4-[2-(4-Chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-N,N-diethyl-3,3-dimethyl-butyramide 
• 898552-38-0 3,3-dimethyl-4-[2-(4-nitro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-butyric acid ethyl ester 
• 898552-40-4 N-hydroxy-3,3-dimethyl-4-[2-(4-nitro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-butyramide 
• 898552-45-9 4-[2-(4-Chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-N-(2-dimethylamino-ethyl)-3,3-dimethyl-butyramide 
• 898552-52-8 ({4-[2-(4-Chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-3,3-dimethyl-butyryl}-methyl-amino)-acetic acid 
• 898552-49-3 {4-[2-(4-Chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-3,3-dimethyl-butyrylamino}-acetic acid 
• 898552-48-2 2-(4-Chloro-phenyl)-5-(2,2-dimethyl-4-morpholin-4-yl-4-oxo-butyl)-4-thioxo-4,5-dihydro-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-6-one 
• 898552-46-0 4-[2-(4-Chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-N-(3-dimethylamino-propyl)-3,3-dimethyl-butyramide 
• 898552-47-1 2-(4-Chloro-phenyl)-5-[2,2-dimethyl-4-(4-methyl-piperazin-1-yl)-4-oxo-butyl]-4-thioxo-4,5-dihydro-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-6-one 
• 898552-50-6 {4-[2-(4-Chloro-phenyl)-6-oxo-4-thioxo-6H-1-oxa-3b,5-diaza-cyclopenta[a]pentalen-5-yl]-3,3-dimethyl-butyrylamino}-acetic acid tert-butyl ester 

Relevant academic research and scientific papers

AMINO PYRAZOLONE DERIVATIVE HAVING CONDENSED RING STRUCTURE

PROBLEM TO BE SOLVED: To provide a compound that has excellent inhibitory action on ATPase activity of TIP48/TIP49 complex and is therefore useful for the treatment of tumor, or a pharmacologically acceptable salt thereof. SOLUTION: The present invention provides a compound having a structure represented by general formula (I), its pharmacologically acceptable salt, or a pharmaceutical composition comprising the compound (where R3, R4, R5, R6, R7, W, X, Y, and Z are as defined in the specifications). SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

PYRAZOLONE DERIVATIVE HAVING CYCLIC SIDE CHAIN

PROBLEM TO BE SOLVED: To provide a compound that has excellent inhibitory action on ATPase activity of TIP48/TIP49 complex and is therefore useful for the treatment of tumor, or a pharmacologically acceptable salt thereof. SOLUTION: The present invention provides a compound having a structure represented by general formula (I), its pharmacologically acceptable salt, or a pharmaceutical composition comprising the compound (where R1, R2, R3, R4, R5, R6, R7, W, and Z are as defined in the specifications). SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

AMINOPYRAZOLONE DERIVATIVE

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which has an excellent inhibitory action on the ATPase activity of a TIP48/TIP49 complex and as such, is useful for the treatment of tumors. [Solution] The present invention provides a compound having a structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the present specification.

Rigidified Compounds for Modulating Heparanase Activity

Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.